Header Logo

Connection

WEN-JEN HWU to Antineoplastic Combined Chemotherapy Protocols

Back to Details
This is a "connection" page, showing publications WEN-JEN HWU has written about Antineoplastic Combined Chemotherapy Protocols.
WEN-JEN HWU
Connection Strength
0.847
Antineoplastic Combined Chemotherapy Protocols
  1. A phase I study of decitabine with pegylated interferon a-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. 2014 Oct; 32(5):969-75.
    View in: PubMed
    Score: 0.103
  2. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res. 2010 Dec; 20(6):501-6.
    View in: PubMed
    Score: 0.081
  3. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Jun 01; 106(11):2445-51.
    View in: PubMed
    Score: 0.059
  4. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005 Jun 15; 103(12):2590-7.
    View in: PubMed
    Score: 0.055
  5. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3351-6.
    View in: PubMed
    Score: 0.049
  6. Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res. 2002 Aug; 12(4):381-7.
    View in: PubMed
    Score: 0.045
  7. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol. 2002 Jun 01; 20(11):2610-5.
    View in: PubMed
    Score: 0.045
  8. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.035
  9. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815.
    View in: PubMed
    Score: 0.033
  10. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. Melanoma Res. 2016 12; 26(6):604-608.
    View in: PubMed
    Score: 0.031
  11. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study. Cancer Chemother Pharmacol. 1995; 36(5):373-8.
    View in: PubMed
    Score: 0.027
  12. Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov; 14(11):1709-18.
    View in: PubMed
    Score: 0.026
  13. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8.
    View in: PubMed
    Score: 0.026
  14. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.022
  15. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival? Melanoma Res. 2011 Feb; 21(1):84-90.
    View in: PubMed
    Score: 0.020
  16. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma. Am J Clin Oncol. 2009 Oct; 32(5):509-14.
    View in: PubMed
    Score: 0.019
  17. A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest. 2009 Aug; 27(7):756-63.
    View in: PubMed
    Score: 0.018
  18. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.018
  19. Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2009 Jun; 64(1):161-7.
    View in: PubMed
    Score: 0.018
  20. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest. 2008 Jul; 26(6):624-33.
    View in: PubMed
    Score: 0.017
  21. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008 Apr; 5(2):201-7.
    View in: PubMed
    Score: 0.017
  22. A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res. 1997 Apr; 7(2):147-51.
    View in: PubMed
    Score: 0.016
  23. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer. 2006 Oct 15; 107(8):1883-90.
    View in: PubMed
    Score: 0.015
  24. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005 Jun; 6(6):438-9.
    View in: PubMed
    Score: 0.014
  25. Systemic chemotherapy. Clin Plast Surg. 2000 Jul; 27(3):451-61, ix-x.
    View in: PubMed
    Score: 0.010
  26. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 10 01; 26(19):5086-5091.
    View in: PubMed
    Score: 0.010
  27. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.009
  28. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.